Related Experiment Video
Updated: Jul 7, 2025
Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
Comparison of Adjuvant Clindamycin vs Linezolid for Severe Invasive Group A Streptococcus Skin and Soft Tissue
Emily L Heil1, Harpreet Kaur2, Anthony Atalla3
1Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Background:
Linezolid may be an option for severe group A Streptococcus (GAS) infections based on its potent in vitro activity and antitoxin effects, but clinical data supporting its use over clindamycin are limited. This study evaluated treatment outcomes in patients with severe GAS skin and soft tissue infections who received either linezolid or clindamycin.
Methods:
This retrospective single-center cohort study examined patients with GAS isolated from blood and/or tissue cultures with invasive soft tissue infection or necrotizing fasciitis who underwent surgical debridement and received linezolid or clindamycin for at least 48 hours. The primary outcome was percentage change in Sequential Organ Failure Assessment (SOFA) score from baseline through 72 hours of hospitalization.
Results:
After adjustment for time to first surgical intervention among patients with a baseline SOFA score >0 (n = 23 per group), there was no difference in reduction of SOFA score over the first 72 hours in patients receiving clindamycin vs linezolid. In the entire cohort (n = 26, clindamycin; n = 29, linezolid), there was no difference in inpatient mortality (2% vs 1%) or any secondary outcomes, including duration of vasopressor therapy, intensive care unit length of stay, and antibiotic-associated adverse drug events.
Conclusions:
There was no difference in reduction of critical illness as measured by SOFA score between baseline and 72 hours among patients treated with clindamycin vs linezolid. Given its more favorable side effect profile, linezolid may be a viable option for the treatment of serious GAS infections and should be further studied.
Insights
Linezolid and clindamycin showed similar effectiveness in treating severe group A Streptococcus infections. Both antibiotics resulted in comparable reductions in organ failure scores and patient mortality.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Severe group A Streptococcus (GAS) infections pose significant clinical challenges.
- Linezolid demonstrates potent in vitro activity and antitoxin effects against GAS.
- Limited clinical data exist comparing linezolid to clindamycin for severe GAS infections.
Purpose of the Study:
- To compare treatment outcomes between linezolid and clindamycin in patients with severe GAS skin and soft tissue infections.
- To evaluate the efficacy of linezolid versus clindamycin in reducing organ dysfunction.
Main Methods:
- Retrospective single-center cohort study.
- Inclusion of patients with invasive GAS infections (soft tissue infection or necrotizing fasciitis) requiring surgical debridement.
- Comparison of Sequential Organ Failure Assessment (SOFA) score changes between linezolid and clindamycin groups.
Main Results:
- No significant difference in SOFA score reduction within 72 hours between linezolid and clindamycin groups, even after adjusting for surgical intervention time.
- No differences observed in inpatient mortality, vasopressor duration, ICU length of stay, or adverse drug events between the two treatment groups.
- The study included 26 patients on clindamycin and 29 patients on linezolid.
Conclusions:
- Linezolid and clindamycin are comparable in reducing critical illness severity (SOFA score) in severe GAS infections.
- Linezolid presents a viable treatment option due to its potentially more favorable side effect profile.
- Further research is warranted to fully elucidate the role of linezolid in treating severe GAS infections.
